« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 122, Issue 1
, Pages
44-48
, July 2008
Sublingual immunotherapy for large local reactions caused by honeybee sting: A double-blind, placebo-controlled trial
-
Peak maximal diameter (in centimeters) of the LLR in the SLIT-treated (left) and placebo-treated (right) patients at baseline and after 6 months. Medians are indicated as horizontal thick arrows. Stat
Peak maximal diameter (in centimeters) of the LLR in the SLIT-treated (left) and placebo-treated (right) patients at baseline and after 6 months. Medians are indicated as horizontal thick arrows. Statistically significant differences are indicated at the top. NS, Not significant.
-
Mean (SEM) honeybee-specific IgE (left) and specific total IgG (right) levels in the active and placebo groups before and after treatment. Values are expressed in kilounits per liter. NS, Not significMean (SEM) honeybee-specific IgE (left) and specific total IgG (right) levels in the active and placebo groups before and after treatment. Values are expressed in kilounits per liter. NS, Not significant.
The sublingual immunotherapy and matched placebo were kindly provided by Anallergo S.p.A, Florence, Italy.
Disclosure of potential conflict of interest: E. Francescato is employed by Entomon SAS. I. Spadolini owns stock in and is employed by Anallergo. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)00617-9
doi: 10.1016/j.jaci.2008.03.031
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 122, Issue 1
, Pages
44-48
, July 2008
